Anti-androgen Treatments

被引:13
作者
Bachelot, Anne [1 ]
Chabbert-Buffet, Nathalie [2 ]
Salenave, Sylvie [3 ]
Kerlan, Veronique [4 ]
Galand-Portier, Marie-Beatrice
机构
[1] Grp Hosp Pitie Salpetriere, Serv Endocrinol & Med, F-75634 Paris, France
[2] Hop Tenon, Serv Gynecol Obstet, F-75970 Paris, France
[3] Hop Bicetre, Serv Endocrinol & Med Reprod, F-94275 Le Kremlin Bicetre, France
[4] CHU Cavale Blanche, Serv Endocrinol, F-29609 Brest, France
关键词
Anti-androgen; Estrogen plus progestin contraceptives; Spironolactone; Cyproterone Acetate; Futamide; Finasteride; POLYCYSTIC-OVARY-SYNDROME; LONG-TERM TREATMENT; CYPROTERONE-ACETATE; HORMONE AGONIST; ORAL-CONTRACEPTIVES; ETHINYL ESTRADIOL; PLUS FINASTERIDE; HIRSUTE WOMEN; DOUBLE-BLIND; HAIR-GROWTH;
D O I
10.1016/j.ando.2009.12.001
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
1. Estrogen plus progestin contraceptives (EPP) are the first-line treatment of moderate hirsutism and acne in women of child bearing age (grade C). 2. CPA, 50 mg/day, 20 days out of 28, associated With estrogen is the first-line treatment of "moderate to severe hirsutism" in women of childbearing age (grade C). 3. Spironolactone. given as a contraceptive, Call be proposed as a second-line treatment in case of side effects or counter-indications to CPA ill moderate to severe hirsutism (grade C) in women of childbearing age. No market authorization in this indication. 4. Flutamide or Finasteride are "only" to be used under the guise of contraception as a "thirdline therapy" in cases of severe hirsutism, the presence of side effects or counter-indications to EPP CPA 50 mg/day or spironolactone (grade C). No Market authorization in this indication 5. There is no indication for GnRH analogs as an anti-androgen treatment in women of childbearing age given the current therapeutic alternatives (grade C) 6. Only long-term hair removal treatments can he proposed (grade C): electrolysis or laser hair removal. (C) 2010 Published by Elsevier Masson SAS.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 52 条
[1]
TREATMENT OF HIRSUTISM WITH A GONADOTROPIN-RELEASING-HORMONE AGONIST (NAFARELIN) [J].
ANDREYKO, JL ;
MONROE, SE ;
JAFFE, RB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (04) :854-859
[2]
[Anonymous], 1993, SPECIALIST
[3]
Hirsutism and acne in polycystic ovary syndrome [J].
Archer, JS ;
Chang, RJ .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2004, 18 (05) :737-754
[4]
The evaluation and management of hirsutism [J].
Azziz, R .
OBSTETRICS AND GYNECOLOGY, 2003, 101 (05) :995-1007
[5]
LEUPROLIDE AND ESTROGEN VERSUS ORAL-CONTRACEPTIVE PILLS FOR THE TREATMENT OF HIRSUTISM - A PROSPECTIVE RANDOMIZED STUDY [J].
AZZIZ, R ;
OCHOA, TM ;
BRADLEY, EL ;
POTTER, HD ;
BOOTS, LR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (12) :3406-3411
[6]
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity [J].
Baillargeon, JP ;
Jakubowicz, DJ ;
Iuorno, MJ ;
Jakubowicz, S ;
Nestler, JE .
FERTILITY AND STERILITY, 2004, 82 (04) :893-902
[7]
Balfour J A, 2001, Am J Clin Dermatol, V2, P197
[8]
Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism [J].
Batukan, C ;
Muderris, II .
FERTILITY AND STERILITY, 2006, 85 (02) :436-440
[9]
Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism [J].
Breitkopf, DM ;
Rosen, MP ;
Young, SL ;
Nagamani, M .
CONTRACEPTION, 2003, 67 (05) :349-353
[10]
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne [J].
Brown, Julie ;
Farquhar, Cindy ;
Lee, Olivia ;
Toomath, Robyn ;
Jepson, Ruth G. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (02)